BeiGene Ltd

BGNE

Company Profile

  • Business description

    Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue.

  • Contact

    c/o Mourant Governance Services (Cayman) Limited
    94 Solaris Avenue, Camana Bay
    Grand CaymanKY1-1108
    CYM

    T: +1 345 949-4123

    E: ir@beigene.com

    https://www.beigene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    9,000

BeiGene Ltd News & Analysis

stocks

These Chinese stocks are at risk of being delisted from US exchanges

Five companies, including Yum China, may delist by 2024 if they are unable to comply with US auditing standards.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,397.6017.900.21%
CAC 407,409.1158.740.80%
DAX 4019,254.97177.430.93%
Dow JONES (US)42,052.19288.730.69%
FTSE 1008,177.1567.050.83%
HKSE20,506.43189.100.93%
NASDAQ18,239.92144.770.80%
Nikkei 22538,053.671,027.58-2.63%
NZX 50 Index12,582.7923.510.19%
S&P 5005,728.8023.350.41%
S&P/ASX 2008,136.9018.100.22%
SSE Composite Index3,272.017.81-0.24%

Market Movers